SAXAGLIPTIN: A NEW ADD-ON TREATMENT FOR PATIENTS WITH TYPE 2 DIABETES

Landsteiner Hall

Tuesday, 29 September 2009, 14:30 - 17:00

Chairman:	Anthony Barnett, UK
14:30 - 14:40	Introduction Anthony Barnett, UK Lectures
14:40 - 14:55	The overall burden of type 2 diabetes Clifford Bailey, UK
14:55 - 15:10	Scientiﬁc rationale for DPP-4 inhibition Jens Juul Holst, DK
15:10 - 15:25	Clinical overview of saxagliptin Julio Rosenstock, US
15:25 - 15:40	Achieving targets safely: role of DPP-4 inhibitors Anthony Barnett, UK
15:40 - 15:50	Questions and comments Panel Discussion
15:50 - 16:00	Bernard Charbonnel, FR
16:00 - 16:10	Stefan R. Bornstein, DE
16:10 - 16:20	Eugene J. Barrett, US
16:20 - 16:30	Emanuele Bosi, IT
16:30 - 16:55	Questions and comments
16:55 - 17:00	Closing Remarks Anthony Barnett, UK